CIBC World Markets Keeps Buy On Teva Pharmaceutical

Analyst Elliot Wilbur says Teva's earnings will get a boost now that the patent for Relafen is invalidated

Teva Pharmaceutical (TEVA ) shares jumped Wednesday after the company won a U.S. lawsuit that will pave the way for the company to market a generic version of GlaxoSmithKline's (GSK ) Relafen arthritis drug. The Israeli drugmaker says the newly launched generic version of Relafen and higher sales of its multiple sclerosis drug Copaxone will push earnings for the second half of 2001 higher than previously expected.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.